Cancer symptom card scheme launched across community pharmacies Exclusive: The ‘Not normal for you?’ scheme will be rolled out across more than 1,000 community pharmacies in the UK, aimed to overcome barriers for people to see their GP.…
Routine delays: the cancer services struggling to treat patients on time Demand for cancer treatment continues to rise while workforce numbers fall, leaving NHS cancer services calling for help as they enter “crisis management”.…
Medicines regulator approves anastrozole for prevention of breast cancer in post-menopausal women NHS England says around 289,000 women at moderate or high risk of breast cancer could benefit from anastrozole.…
Community pharmacy pilot service to refer patients with cancer symptoms expanded Exclusive: The East of England North Cancer Alliance and South East London Cancer Alliance plan to begin offering the NHS community pharmacy ‘early diagnosis of cancer’ pilot service in 2024.…
Pilot sites for community pharmacies to refer patients with signs of possible cancer delayed Exclusive: Pharmacy representatives from two of the the four areas that had signed up to provide the pilot service have said they are experiencing delays, while one cancer alliance has pulled out of the scheme.…
Pharmacists have a vital role in shining a brighter light on blood cancer More than three quarters of patients with blood cancer consider their illness to be a “hidden cancer” because of a lack of public understanding — pharmacists can help to change that.…
BTK inhibitors: what pharmacists need to know In this episode of The PJ Pod, we consider the impact bruton tyrosine kinase (BTK) inhibitors have had on care for patients with B-cell malignancies and explore how pharmacists can help patients get the best out of their treatment regimens.… Supported content
‘Game changing’ cancer drug to be withdrawn by manufacturer Takeda — manufacturer of Exkivity (mobocertinib), which is used to treat a rare form of lung cancer — has announced it intends to withdraw the drug after it did not meet its primary endpoint in a phase III trial.…
‘World first’ anticancer jab to reduce treatment times by 75%, says NHS England NHS England has announced that it will offer atezolizumab via subcutaneous injection, bringing treatment times down from 30 minutes to as little as 7 minutes.…
Pharmacy teams told to ‘urgently’ order unlicensed imports of chemotherapy drugs in shortage warning Exclusive: A ‘Tier 3 — high impact’ alert has been issued for the platinum-based chemotherapy agents cisplatin, carboplatin and oxaliplatin.…
